Context Therapeutics Inc. announced on May 5, 2025, a transition in its Chief Medical Officer (CMO) role. Dr. Claudio Dansky Ullmann will be leaving the company effective May 10, 2025.
Dr. Karen Smith, a current member of Context's Board of Directors, has been appointed as interim Chief Medical Officer. Dr. Smith will serve in this dual capacity while the company conducts a search for a new, full-time CMO.
Dr. Smith brings over 20 years of experience in drug development, having held senior leadership roles at companies such as Jazz Pharmaceuticals, Allergan, AstraZeneca, and Bristol Myers Squibb. Her appointment ensures continuity in strategic guidance for the company’s clinical development programs during this transition period.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.